News
Following a pre-specified interim analysis, an independent Data Safety Monitoring Board (DSMB) recommended the pivotal Phase 3 trial (DRAGON) of Tinlarebant in adolescent Stargardt disease (STGD1) pat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback